VKTX Viking Therapeutics Inc.

8.1
-0.16  -2%
Previous Close 8.26
Open 8.26
Price To Book 1.96
Market Cap 583086778
Shares 71,986,022
Volume 1,673,324
Short Ratio
Av. Daily Volume 2,954,399

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 additional NAFLD data to be presented at EASL April 11-14, 2019 with Phase 2b trial to be initiated 2H 2019.
VK2809
Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.
VK5211
Acute Hip Fracture

Latest News

  1. Harry Boxer: 3 biotech stocks with momentum
  2. Edited Transcript of VKTX earnings conference call or presentation 13-Mar-19 8:30pm GMT
  3. VKTX: Phase 2b Trial for VK2809 to Initiate 2H19…
  4. Viking Therapeutics (VKTX) Q4 2018 Earnings Conference Call Transcript
  5. Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
  6. Shareholders Are Raving About How The Viking Therapeutics (NASDAQ:VKTX) Share Price Increased 346%
  7. 3 Stocks That Could Double Your Money
  8. Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2018 on March 13, 2019
  9. Is Viking Therapeutics a Buy?
  10. Viking Therapeutics to Participate in Upcoming Investor Conferences and Events
  11. Research Report Identifies Wolverine World Wide, Viking Therapeutics, Ampio Pharmaceuticals, ArcelorMittal, Delphi Technologies, and Unit with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  12. Healthcare Companies Investors are Watching
  13. 4 Healthcare Stocks Looking to Start Strong on Tuesday (2/19/19)
  14. 3 Top Biotech Stocks to Buy in February
  15. Should You Buy Viking Therapeutics After Gilead Drug Failure?
  16. Gilead's (GILD) Late-Stage Study on Liver Disease Drug Fails
  17. Here's Why Viking Therapeutics Rose as Much as 13.9% Today
  18. These Healthcare Stocks Could Surpass Investor Expectations
  19. Viking Therapeutics Breaks Out After Gilead's Clinical Failure
  20. Ligand Pharmaceuticals Inc (LGND) Q4 2018 Earnings Conference Call Transcript